Interesting Stocks: China Techfaith Wireless Comm., Melco Crown Entertainment Limited (NASDAQ:MPEL), American Airlines Group (NASDAQ:AAL), Sophiris Bio (NASDAQ:SPHS)

China Techfaith Wireless Comm. Tech. Ltd (NASDAQ:CNTF) ended the last trading day at $0.71. Company weekly volatility is calculated as 5.39% and price to cash ratio as 3.24. China Techfaith Wireless Comm. Tech. Ltd (NASDAQ:CNTF) showed a weekly performance of -5.33%.

China Techfaith Wireless Comm. Tech. Ltd (NASDAQ:CNTF) announced that it will hold a conference call to discuss the Company’s financial results for the third quarter of 2015 and its business outlook. The dial-in number for the live audio call, which will begin on Wednesday, November 25, 2015

On 18 November, Melco Crown Entertainment Limited (NASDAQ:MPEL) shares increased 1.19% and was closed at $16.65. MPEL EPS growth in last 5 year was 30.20%. Melco Crown Entertainment Limited (NASDAQ:MPEL) year to date (YTD) performance is -34.08%.

Melco Crown Entertainment Limited (NASDAQ:MPEL) announced that its subsidiary, Studio City Company Limited, as the borrower under the US$1.4 billion Studio City term loan and revolving credit facility, has received the requisite lender consent to amend the loan documentation as proposed by the Studio City borrowing group.

American Airlines Group Inc. (NASDAQ:AAL) ended the last trading day at $41.75. Company weekly volatility is calculated as 2.62% and price to cash ratio as 2.97. American Airlines Group Inc. (NASDAQ:AAL) showed a weekly performance of -5.95%.

American Airlines Group Inc. (NASDAQ:AAL) has been honored once again by the Human Rights Campaign (HRC) with the highest possible rating in the prestigious 2016 Corporate Equality Index (CEI). American was the only airline to achieve a perfect score when the CEI launched in 2002, and is one of only a small number of corporations to do so every year since.

Sophiris Bio, Inc. (NASDAQ:SPHS) caters to the Healthcare space. Its weekly performance is -29.69%. On the last day of trading company shares ended up at $2.25. Sophiris Bio, Inc. (NASDAQ:SPHS) distance from 50-day simple moving average (SMA50) is -20.37%.

On 10 November, Sophiris Bio, Inc. (NASDAQ:SPHS) announced final results from its Phase 3 “PLUS-1” study of PRX302 as a treatment for lower urinary tract symptoms of benign prostatic hyperplasia (BPH, enlarged prostate). PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score (IPSS) total score from baseline over 12 months compared to the vehicle-only control group (7.60 vs. 6.58 point overall improvement; p = 0.043), the primary endpoint of the study.